Steven Cohen C4 Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 278,580 shares of CCCC stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

278,580

Previous 278,580 -0.0%

Holding current value

$1.68 Million

Previous $1.29 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.05 - $8.1 $2.54 Million - $5.09 Million	-627,892 Reduced 69.27%	278,580 $1.29 Million
Q1 2024 May 15, 2024	SELL	$5.3 - $11.0 $5.59 Million - $11.6 Million	-1,054,887 Reduced 53.78%	906,472 $7.41 Million
Q4 2023 Feb 14, 2024	BUY	$1.18 - $6.03 $2.3 Million - $11.7 Million	1,945,338 Added 12142.43%	1,961,359 $11.1 Million
Q3 2023 Nov 14, 2023	BUY	$1.81 - $3.89 $17,129 - $36,814	9,464 Added 144.33%	16,021 $29,000
Q2 2023 Aug 14, 2023	SELL	$2.75 - $3.77 $47,234 - $64,753	-17,176 Reduced 72.37%	6,557 $18,000
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $73,572 - $214,071	23,733 New	23,733 $74,000
Q2 2022 Aug 15, 2022	SELL	$5.06 - $26.46 $2.55 Million - $13.3 Million	-503,888 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $10.1 Million - $16.7 Million	503,888 New	503,888 $12.2 Million
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $5.88 Million - $9.37 Million	-200,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $1.24 Million - $1.74 Million	34,400 Added 20.77%	200,000 $8.94 Million
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $5.03 Million - $6.99 Million	165,600 New	165,600 $6.27 Million

Others Institutions Holding CCCC

# of Institutions

127

Shares Held

53.8M

Call Options Held

331K

Put Options Held

145K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $295M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account